Ironshore Drug Patent Portfolio

Ironshore owns 1 orange book drug protected by 16 US patents Given below is the list of Ironshore's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10182995 Compositions for treatment of attention deficit hyperactivity disorder 23 Mar, 2032
Active
US10292937 Methods of treatment of attention deficit hyperactivity disorder 23 Mar, 2032
Active
US10617651 Compositions for treatment of attention deficit hyperactivity disorder 23 Mar, 2032
Active
US10881618 Compositions for treatment of attention deficit hyperactivity disorder 23 Mar, 2032
Active
US10905652 Compositions for treatment of attention deficit hyperactivity disorder 23 Mar, 2032
Active
US11241391 Compositions for treatment of attention deficit hyperactivity disorder 23 Mar, 2032
Active
US11241392 Compositions for treatment of attention deficit hyperactivity disorder 23 Mar, 2032
Active
US11911518 Compositions for treatment of attention deficit hyperactivity disorder 23 Mar, 2032
Active
US8916588 Methods for treatment of attention deficit hyperactivity disorder 23 Mar, 2032
Active
US8927010 Compositions for treatment of attention deficit hyperactivity disorder 23 Mar, 2032
Active
US9023389 Compositions for treatment of attention deficit hyperactivity disorder 23 Mar, 2032
Active
US9028868 Methods and compositions for treatment of attention deficit disorder 23 Mar, 2032
Active
US9034902 Methods for treatment of attention deficit hyperactivity disorder 23 Mar, 2032
Active
US9283214 Compositions for treatment of attention deficit hyperactivity disorder 23 Mar, 2032
Active
US9498447 Compositions for treatment of attention deficit hyperactivity disorder 23 Mar, 2032
Active
US9603809 Methods of treatment of attention deficit hyperactivity disorder 23 Mar, 2032
Active


Given below is the list of recent legal activities going on the following drug patents of Ironshore.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 4th Yr, Small Entity 23 Jul, 2025 US11241391
Payment of Maintenance Fee, 4th Yr, Small Entity 23 Jul, 2025 US11241392
Email Notification 01 Apr, 2025 US10617651
Change in Power of Attorney (May Include Associate POA) 01 Apr, 2025 US11241391
Change in Power of Attorney (May Include Associate POA) 01 Apr, 2025 US10905652
Email Notification 01 Apr, 2025 US11241391
Change in Power of Attorney (May Include Associate POA) 01 Apr, 2025 US10617651
Change in Power of Attorney (May Include Associate POA) 01 Apr, 2025 US10881618
Email Notification 01 Apr, 2025 US10881618
Email Notification 01 Apr, 2025 US10905652
Email Notification 28 Mar, 2025 US9028868
Change in Power of Attorney (May Include Associate POA) 28 Mar, 2025 US11241392
Change in Power of Attorney (May Include Associate POA) 28 Mar, 2025 US9028868
Email Notification 28 Mar, 2025 US9603809
Change in Power of Attorney (May Include Associate POA) 28 Mar, 2025 US10292937


Ironshore's Family Patents

Ironshore drugs have patent protection in a total of 14 countries. It's US patent count contributes only to 49.1% of its total global patent coverage. Click below to unlock the full patent family tree.

Family Patents



Ironshore Drug List

Given below is the complete list of Ironshore's drugs and the patents protecting them.


1. Jornay Pm

Jornay Pm is protected by 16 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10182995 Compositions for treatment of attention deficit hyperactivity disorder 23 Mar, 2032
(6 years from now)
Active
US10292937 Methods of treatment of attention deficit hyperactivity disorder 23 Mar, 2032
(6 years from now)
Active
US10617651 Compositions for treatment of attention deficit hyperactivity disorder 23 Mar, 2032
(6 years from now)
Active
US10881618 Compositions for treatment of attention deficit hyperactivity disorder 23 Mar, 2032
(6 years from now)
Active
US10905652 Compositions for treatment of attention deficit hyperactivity disorder 23 Mar, 2032
(6 years from now)
Active
US11241391 Compositions for treatment of attention deficit hyperactivity disorder 23 Mar, 2032
(6 years from now)
Active
US11241392 Compositions for treatment of attention deficit hyperactivity disorder 23 Mar, 2032
(6 years from now)
Active
US11911518 Compositions for treatment of attention deficit hyperactivity disorder 23 Mar, 2032
(6 years from now)
Active
US8916588 Methods for treatment of attention deficit hyperactivity disorder 23 Mar, 2032
(6 years from now)
Active
US8927010 Compositions for treatment of attention deficit hyperactivity disorder 23 Mar, 2032
(6 years from now)
Active
US9023389 Compositions for treatment of attention deficit hyperactivity disorder 23 Mar, 2032
(6 years from now)
Active
US9028868 Methods and compositions for treatment of attention deficit disorder 23 Mar, 2032
(6 years from now)
Active
US9034902 Methods for treatment of attention deficit hyperactivity disorder 23 Mar, 2032
(6 years from now)
Active
US9283214 Compositions for treatment of attention deficit hyperactivity disorder 23 Mar, 2032
(6 years from now)
Active
US9498447 Compositions for treatment of attention deficit hyperactivity disorder 23 Mar, 2032
(6 years from now)
Active
US9603809 Methods of treatment of attention deficit hyperactivity disorder 23 Mar, 2032
(6 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Jornay Pm's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List